Immunology and Microbiology
Alemtuzumab
100%
Leukemia Cell
79%
Conditioning
77%
CD38
56%
Overall Survival
52%
Graft-Versus-Host Disease
47%
B Cell
39%
CD49d
38%
Myeloid
38%
Allogeneic Hematopoietic Stem Cell Transplantation
33%
T Cell
32%
Lymphocyte
32%
Hematopoietic Stem Cell Transplantation
31%
Engraftment
29%
Allograft
24%
Chronic Graft Versus Host Disease
24%
Coculture
22%
Allogeneic Stem Cell Transplantation
22%
Disease Free Survival
21%
Dendritic Cell
21%
Hematopoietic Cell
19%
Cell Migration
17%
Comorbidity
15%
CD44
15%
Bcl-2
14%
Lymph Node
14%
Vascular Endothelium
14%
Nonmyeloablative Stem Cell Transplantation
14%
Stem Cell Transplantation
14%
Genetic Transcription
14%
Cell Transplantation
12%
CD3 Antigen
11%
Chemokine
11%
Interleukin 6
10%
CD80
9%
CD19
8%
Mental Capacity
8%
Acute Graft Versus Host Disease
8%
T Cell Activation
8%
CXCR4
8%
Upregulation
8%
Interleukin 2
8%
T Cell Proliferation
7%
Lineages
7%
Cell Survival
7%
Fibroblast
7%
B-Cell Receptor
7%
Gammopathy
7%
Rituximab
7%
Lymphocyte Migration
7%
Medicine and Dentistry
Alemtuzumab
75%
B-Cell Chronic Lymphocytic Leukemia
70%
Graft Versus Host Reaction
44%
Myelodysplastic Syndrome
42%
Overall Survival
42%
Allogeneic Hematopoietic Stem Cell Transplantation
39%
Reduced Intensity Conditioning
36%
Leukemia Cell
34%
Acute Myeloid Leukemia
28%
Diseases
27%
Hematopoietic Stem Cell Transplantation
27%
Volunteer
26%
Engraftment
24%
Fludarabine
22%
Allograft
22%
Allogeneic Stem Cell Transplantation
22%
Hematopoietic Cell
21%
Chronic Graft Versus Host Disease
21%
Follicular Lymphoma
21%
Busulfan
19%
Stem Cell Therapy
19%
Donor Lymphocyte Infusion
19%
Conditioning
18%
Antiapoptotic
15%
Lymphoproliferative Disease
15%
Cell Migration
14%
T Cell
14%
Vascular Endothelium
14%
Genetic Transcription
14%
Nonmyeloablative Stem Cell Transplantation
14%
Rituximab
14%
Hematologic Malignancy
13%
Melphalan
13%
Infection
12%
Comorbidity
12%
Disease Free Survival
11%
B Cell
10%
Graft Failure
10%
Chemokine
9%
Neoplasm
9%
Outpatient
9%
Non-Relapse Mortality
9%
Carmustine
8%
Acute Graft Versus Host Disease
8%
Chemokine Receptor
8%
Oncology
8%
Bone Marrow Transplantation
8%
Cumulative Incidence
8%
Guanosine Triphosphatase
8%
Neutropenia
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
73%
Alemtuzumab
34%
Diseases
29%
Overall Survival
25%
Antiapoptotic
17%
Fludarabine
14%
Acute Myeloid Leukemia
14%
Ibrutinib
14%
Myelodysplastic Syndrome
14%
Rituximab
14%
Chronic Graft Versus Host Disease
14%
Chemotherapy
12%
Graft Versus Host Reaction
11%
Ofatumumab
10%
Remission
10%
Neoplasm
8%
Chemokine
8%
Neutropenia
7%
Clinical Trial
7%
Progression Free Survival
7%
Macrophage Inflammatory Protein
7%
Synapsin II
7%
Combination Therapy
7%
Gelatinase B
7%
Daclizumab
7%
Lymphoproliferative Disease
7%
Oxaliplatin
7%
Gammopathy
7%
Human T-Lymphotropic Virus 1
7%
Gemcitabine
7%
T Cell Leukemia
7%
Non Insulin Dependent Diabetes Mellitus
7%
Hyperglycemia
7%
Secondary Acute Myeloid Leukemia
7%
Immunoglobulin Enhancer Binding Protein
7%
Acute Graft Versus Host Disease
7%
Tumor Microenvironment
7%
Acute Lymphoblastic Leukemia
7%
B Lymphocyte Receptor
7%
Venetoclax
7%
Chimeric Antigen Receptor
7%
Receptor Antagonist
7%
Stress Activated Protein Kinase
7%
Lamivudine
7%
Hepatitis B Virus
7%
Granulocyte Colony Stimulating Factor
7%
Hematologic Malignancy
7%
Chemokine Receptor
7%
Glucocorticoid
7%
Beta Chemokine
7%